Arrowhead Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Biotechnology | Market Cap: ₹11.1K Cr
- REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch. - No specific future guidance on earnings, operating earnings, profits, or EPS was provided during the call.
From Arrowhead Pharmaceuticals, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹79.05
Market Cap
₹11.1K Cr
Revenue Rank
Margin Rank
How does Arrowhead Pharmaceuticals, Inc. rank in Biotechnology?
Compare Arrowhead Pharmaceuticals, Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch.
- →Approximately 85% of prescriptions are from APOC3 class-naive patients, indicating growth via newly identified FCS patients.
- →Prescription growth shows geographic breadth across the U.S., suggesting scalable patient identification and durable demand.
- →Early patient persistence and satisfaction data are encouraging for sustained usage.
- →Plans to expand REDEMPLO into the severe hypertriglyceridemia (SHTG) market with SHASTA-3 and SHASTA-4 Phase III data readout expected in Q3 2026.
- →Anticipated clinical data readouts (ARO-DIMER-PA, ARO-MAPT) and additional obesity/NASH programs could drive pipeline growth and future revenue.
- →The company aims to leverage commercial capabilities established for FCS to support future launches, including potential SHTG and HoFH indications.
- →Balance sheet strength (~$1.8 billion cash and investments) provides flexibility to fund expansion and commercialization efforts.
📈 Profitability & Margins
Rank 3- →No specific future guidance on earnings, operating earnings, profits, or EPS was provided during the call.
- →Q2 FY26 reported a net loss of $132.7 million ($0.93 per share) compared to net income in prior year due to one-time transaction revenue in 2025.
- →Commercial momentum for REDEMPLO continues with growing prescriptions, supporting expansion.
- →Upcoming key catalysts in H2 2026 (SHASTA-3/4, MURI-3 readouts, ARO-DIMER-PA, ARO-MAPT data) expected to drive pipeline value.
- →Large cash position (~$1.8 billion) provides financial flexibility for R&D and commercialization.
- →Management emphasizes focus on advancing clinical pipeline and expanding commercial footprint, implying potential long-term growth.
- →No explicit earnings or EPS projections were disclosed; future financial performance will depend on clinical successes and market adoption.
🏗️ Capital Expenditure Plans
Yes- →Arrowhead conducted its largest fundraising ever in the recent quarter, raising over $1 billion through public offerings of convertible senior notes and common stock, strengthening the balance sheet to support ongoing and future investments.
- →Capital investment is focused on advancing clinical development programs, including Phase III studies for plozasiran in severe hypertriglyceridemia (SHTG) and early-stage programs like dimer and MAPT.
- →Strategic investments also include expanding commercial infrastructure to support REDEMPLO and future potential launches (e.g., SHTG and HoFH treatments).
- →The company entered an exclusive worldwide license agreement with Madrigal for ARO-PNPLA3 to advance this asset via partnership rather than internal capital allocation.
- →Capital allocation favors wholly owned pipeline advancement while selectively partnering programs (e.g., C3 and Factor B) to optimize ROI and resource distribution.
- →No immediate mention of significant new capital projects outside clinical development and commercialization expansion.
💰 Fundraising & Capital Structure
Yes- →In Q2 FY2026, Arrowhead completed its largest fundraising ever, raising over $1 billion.
- →This included approximately $850 million net from January 2026 financing transactions.
- →The financing comprised concurrent offerings of $700 million in 0% coupon convertible senior notes and $230 million in common stock.
- →Both offerings were several times oversubscribed, indicating strong investor confidence.
- →No specific mention of plans for new future fundraising through debt or equity was provided in the call.
- →The company emphasized that this strong balance sheet provides significant financial flexibility to support ongoing clinical development and potential commercialization.
📋 Order Book & Pipeline
No information- →More than 400 prescriptions for REDEMPLO have been written since its launch.
- →Approximately 30 new prescriptions are being written each week currently.
- →Over 10% of these prescriptions are from patients switching from a competitor's APOC3 inhibitor.
- →Prescriptions require full adjudication with payers before becoming paid claims.
- →No specific mention of a detailed current or expected orderbook volume or pending orders beyond prescription data was provided.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
- BridgeBio Pharma, Inc. (Q2 FY26)
BridgeBio Pharma, Inc. Q2 FY26 quarterly results analysis. Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth i
Frequently Asked Questions
What were Arrowhead Pharmaceuticals, Inc. Q2 FY26 results?
- REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold over the quarter and surpassing 400 total prescriptions since launch. - No specific future guidance on earnings, operating earnings, profits, or EPS was provided during the call.
What is Arrowhead Pharmaceuticals, Inc. share price analysis?
Arrowhead Pharmaceuticals, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -18.1 with a market cap of $11,135. Investors should review the full earnings analysis for detailed insights.
Is Arrowhead Pharmaceuticals, Inc. planning capital expenditure?
- Arrowhead conducted its largest fundraising ever in the recent quarter, raising over $1 billion through public offerings of convertible senior notes and common stock, strengthening the balance sheet to support ongoing and future investments.
Keep Arrowhead Pharmaceuticals, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.